INTRODUCTION
At the beginning of the human immunodeficiency virus (HIV) epidemic, diagnosis with an HIV positive status warranted a medical response focused on treating opportunistic infections and providing palliative care. Today, medical management of HIV includes co-morbidities, drug interactions, and other non-AIDS related complications typical of the aging process. Due to the increase in options and quality of treatments, patients with HIV can now have the same life expectancy as a person from the general population provided that adherence to antiretroviral medications is maintained. [1] [2] [3] It was estimated over 1.2 million people live with HIV infection in the United States today. 4 The percentage of persons living with HIV who are 55 years of age or more increased from 13.2% in 2006 to 17.1% in 2009. 5 By the year of 2015, it has previously been extrapolated that half of those living with HIV infection will be 50 years of age or older. [6] [7] It has even been noted that people with HIV may live longer than those without it because of closer follow-up as they age. 8 With this increase in longevity, the paradigm of managing patients with HIV has shifted. Opportunistic infections are far less prevalent than they once were. Effective antiretroviral therapy, even for resistant patients, is readily available. Many patients are now cared for by HIV primary care clinics, with the challenge of most visits primarily being treatment of other chronic disease states such as diabetes, hypertension, and hyperlipidemia.
Appropriate management of such non-infectious co-morbidities is a challenge in any population, but may correlate to a higher burden of disease for individuals infected Pharmacist Impact on HIV Co-Morbidities 4 with HIV. Growing evidence suggests that HIV may accelerate inflammatory processes which promote atherosclerosis, and an increased risk of cardiovascular disease (CVD) in this population has been well established. [9] [10] Certain antiretroviral drugs are also known to induce metabolic changes such as dyslipidemia, lipodystrophy, and insulin resistance. [11] [12] [13] The most common medical co-morbidities for HIV-infected veterans 60
years of age or older were previously defined as hypertension (45%), diabetes (21%), and vascular disease (23%). 14 Additionally, HIV-infected individuals may have a higher prevalence of co-morbidities than uninfected individuals of the same age. 15 The AGEhIV study specifically showed higher rates of hypertension, myocardial infarction, peripheral arterial disease, and renal disease in those with HIV as compared to the general population. 16 In the New York metropolitan area, where this study was performed, there are an estimated 140,000 people living with HIV. 17 Prevalence rates of hypertension, hyperlipidemia, and diabetes have been identified as 26%, 48%, and 13% in a Bronx institution serving an urban, low-income, HIV-positive population similar to ours.
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The pharmacist's role in management of both HIV and chronic disease states has continued to expand over the years. In 2011, the American Academy of HIV Medicine developed a new program to certify pharmacists specializing in HIV management (AAHIVP). 19 Additionally, the Department of Human & Health Services (DHHS)
HIV/AIDS Guidelines recommend the use of multidisciplinary teams, including pharmacists, as the optimal practice model. 20 The advent of collaborative drug therapy The use of CDTM to improve patient outcomes in chronic disease states has been extensively addressed and demonstrated in the literature. [22] [23] [24] A meta-analysis on the role of team-based care involving pharmacists to improve cardiovascular and renal outcomes found patients in the team-based care group to have reduced blood pressure, LDL, HbA1c, and in heart failure patients, reduced all-cause mortality, heart failure events, and hospitalization rates as compared to the usual care group. 22 The impact of CDTM on HIV treatment outcomes has also been studied, primarily in settings such as pharmacist-driven adherence clinics or outpatient pharmacies. 25 Relevant interventions have been classified as medication adherence counseling, patient education, increased rates of HIV testing, antiretroviral regimen selection/initiation/discontinuation, dose adjustment for renal/hepatic impairment, and monitoring for adverse effects and drug interactions. [25] [26] [27] [28] [29] In an HIV-primary care clinic which utilizes an interdisciplinary model, such as 
METHODS
This study was a retrospective cohort study of HIV-positive patients seen at the PATH Center from June 2012 through December 2013. The "interdisciplinary group" served as the intervention group, including a clinical pharmacist in addition to a medical provider. As our institution is a teaching hospital, this group may also include medical and pharmacy residents and students. Both medical and pharmacy disciplines collaborate to determine a final plan of care. Patients who prefer a more private treatment setting may opt out of the interdisciplinary group and be seen individually by a separate physician, nurse practitioner, or physician assistant. These providers do not participate in the interdisciplinary team model and patients under "solo provider" care served as the control group. This research study received Institutional Review Board (IRB) approval.
As the interdisciplinary group contains members from medical and pharmacy, it can be difficult to assign study outcomes to one specific member of the team. To eliminate measurement bias, potential study subjects from the interdisciplinary group solo-provider patients was selected using block randomization from a data query which identified patients seen over the 18-month study period and prescribed anti-hypertensives, lipid lowering agents, or anti-diabetics.
As it is plausible that either group could have seen more complicated patients, the
Charlson Co-morbidity Index (CCI) Scoring System was applied to indicate each patient's severity level for use as a potential confounding variable. This system represents a 10-year mortality risk score and has been validated in both in-patient and out-patient settings. 24, 31 The CCI score was calculated based on patient diagnoses at the beginning of the study period. Although the CCI scoring system assigns a score of 6 points to patients with a diagnosis of AIDS, for our purposes only patients with actively uncontrolled disease and CD4 <200 mg/dL were assigned 6 points towards their total score, considering most of our patients with an AIDS diagnosis have recovered immune function. 32 Electronic medical records of eligible study subjects were retrospectively reviewed and the 18-month follow-up data were collected. The primary outcome was the change from patient's own baseline for systolic and diastolic blood pressure, LDL cholesterol, and HbA1c, which were chosen as surrogate markers for hypertension, hyperlipidemia, and diabetes due to the implications of disease control on risk of cardiovascular events. Secondary outcomes included differences between treatment groups in HIV-related outcomes such as number of drug-drug interactions, viral load, and CD4 counts. Other secondary outcomes were also chosen for their potential impact on cardiovascular disease (CVD) including appropriate use of low-dose aspirin, percent change in reported smoking status, and percent of patients treated according to guideline recommendations. This included appropriateness of cardiovascular medications per JNC 7 and ACC/AHA Joint Guidelines and medication therapy for stroke, coronary artery disease, and congestive heart failure as per most recent AHA guidelines. [33] [34] [35] [36] [37] Smoking cessation is of particular concern for HIV-infected individuals as it is more prevalent in this population and has been shown to contribute to elevated CVD risk, increased rates of pulmonary diseases, and increased infections. [38] [39] [40] was found in comparison of subject characteristics between two groups, this characteristic was treated as a potential confounding factor and included as an independent variable in the regression models. Linear regression analyses with the forward stepwise method were performed to identify potential covariates. General linear model was used to adjust final measures of primary outcomes for the covariate(s).
RESULTS
Baseline characteristics and distribution of co-morbidities is reported in The two groups had similar results in terms of achieving "goal" BP, LDL, and
HbA1c at final visit. Results of secondary outcomes are shown in Table 3 . More patients in the interdisciplinary group as compared to the solo provider group had appropriate therapy prescribed for compelling cardiovascular indications (71.6% vs. 60%), but the difference was not statistically significant. Among those with an indication for aspirin, a significantly higher percent of patients (85.5%) were prescribed the medication in the interdisciplinary group, compared to only 64.9% in the solo provider group (p=0.014).
Among smokers at baseline, the smoking cessation rate over the study time period was doubled in the interdisciplinary group (20.4%) compared to that in the control (11.8%);
however, no significant statistical difference was found (p=0.714). There continued to be significantly fewer drug-drug interactions identified in the interdisciplinary group at the end of follow-up (p=0.023); however, the significance disappears when baseline measure was considered (p=0.432). Regarding HIV-related outcomes, no statistically significant difference was identified for either baseline or final value for CD4 and viral load. have represented a controversial shift away from numerical LDL goals in favor of appropriate prescribing 41 , it is still important to note the significant reduction in cholesterol lowering seen with the interdisciplinary group as patients with HIV are at a higher risk for developing coronary artery disease. [9] [10] The reduction in LDL cholesterol were reflective of pharmacist recommendations of using more appropriate intensity statins. Additionally, although there was no statistical difference between groups regarding blood pressure control, these results are likely no longer relevant as blood pressure goals for primary prevention have become more lenient with the updated hypertension guidelines published in late 2013. 42 Although no statistically significant difference was seen between groups in regards to better blood pressure or diabetes control, the HbA1c reduction of 1.3% seen in the interdisciplinary group may still be interpreted as clinically significant. In addition to the clinical pharmacist involvement in routine clinic visits, patients may also be referred for individual appointments with the pharmacist if further counseling or education is requested. Uncontrolled diabetes represents a significant portion of these one-on-one referrals and such positive diabetes outcomes may be a reflection of this individual attention. As only 17 patients from the solo provider group and 29 patients from the interdisciplinary group were included in this part of the analysis, it is likely that the study was underpowered to detect a significant difference between groups.
The PATH Center serves a primarily Medicaid population with approximately 99% of patients living below the federal poverty level. The care of such patients is often complicated by psychiatric and socioeconomic issues such as drug abuse, depression, and unemployment. 43 Due to such confounding factors, it was suspected that many patients may not achieve therapy goals due to issues with medication access and adherence, rather than inappropriate prescribing habits. This seemed to be true for the interdisciplinary group as only 53.3% of patients achieved adequate blood pressure control over the study time period despite 71.6% being prescribed appropriate therapy. Our interdisciplinary group overall was shown to be more thorough in their prescribing habits, specifically for compelling cardiovascular medications and aspirin for primary or secondary prevention as per JNC, NCEP, AHA, ASA, ACCF, and the U.S. Preventative Services Task Force (USPSTF) recommendations. [33] [34] [35] [36] [37] 44 Smoking cessation can also be more difficult to address in an urban population, particularly in HIV patients who have a high rate of tobacco use. Traditional therapies, such as nicotine replacement therapy, varenicline, and bupropion have been shown to facilitate abstinence in HIV-positive smokers. 45 Unique interventions to address smoking cessation in this population have included nurse-driven interventions, culturally tailored group-based sessions for African-American MSM, and cell-phone delivered intensive counseling sessions, all combined with nicotine replacement therapy (NRT). [46] [47] [48] Studies have suggested that helping HIV-positive smokers develop adaptive strategies to cope with HIV symptom distress may be an effective approach to cessation. 49 It is hypothesized that the heightened awareness and willingness to prescribe pharmacologic interventions by the pharmacy team is behind the doubled rate of smoking cessation in the interdisciplinary group.
Even though there are significant differences in total number of medications (p=0.0014) and drug-drug interactions (p=0.008) between two groups at baseline, both groups had a similar pattern of reduction in drug-drug interactions during the entire study time period (p= NS after adjusting final values for baseline). Certain interactions, such as acid-suppressant medications and rilpivirine or atazanavir, can compromise the efficacy of a patient's antiretroviral regimen. In addition, ritonavir or cobicistat based regimens often result in drug interactions concerning patient safety. Therefore, recognition of interactions is a tremendously important part of any HIV patient's care. 50 We did not expect to find any difference between groups for CD4 counts and viral loads as successful management of these outcomes has become routine since the development of highly active antiretroviral therapy. All providers at the clinic are experienced and fully competent in choosing safe and effective regimens for their patients, with consideration always given to resistance and adherence. As long as patients are compliant with their medications, the CD4 and viral load are expected to respond appropriately. The study data supported our argument by showing no statistical difference between groups at either baseline or final visit for CD4 or viral load. While several studies have reported a significant reduction in viral load with pharmacist involvement [51] [52] [53] [54] [55] , most of these studies were not performed in an HIV primary care clinic such as ours where addressing antiretroviral adherence and simplifying regimens is an integral part of each visit. The true impact of this study was shown in the patient's chronic comorbidities which, as described in the introduction, are frequently now the focus of HIV primary care visits.
Possible limitations for the study include its retrospective design and small sample size for each disease state evaluated. Although the pre-specified number for inclusion was met, power may not have been achieved for disease state specific outcomes as not every patient reviewed had all three co-morbidities. While measures were taken to establish if one group of patients was more medically complicated than the other, differences in psychiatric capacity or socioeconomic status were not captured. These and other confounding variables could have represented significant barriers to medication access or adherence, which subsequently could have influenced outcomes. It is also important to note patient self-selection as a study bias. The intervention and control groups are not randomized as the patient chooses who they would like to receive care from. Personality traits and factors which influence this private decision are unaccounted for in our analysis. The interdisciplinary group also involves medical residents which may be cited as another difference between the intervention and control groups. However, all patients included in the interdisciplinary group were identified only from a pool of patients with documented pharmacist interventions, suggesting that the presence of a clinical pharmacist had significantly impacted the patient's care. Lastly, this study was based on the goals and therapy recommendations of previous disease state guidelines.
Although aforementioned updated guidelines were recently released [41] [42] , the guidelines used in the methodology of this study were considered the gold standard for the vast majority of the follow-up time period.
Despite being a small, single-center study, it is the first of its kind to address the benefit of HIV clinical pharmacist involvement in an HIV primary care clinic for disease state outcomes beyond just HIV. The results of this study showed pharmacist involvement to be beneficial for lipid management, as well as improvement in diabetes, smoking cessation rates, adherence to optimal prescribing recommendations, appropriate use of aspirin, and reduced drug-drug interactions. It is important to note that although this study primarily reported surrogate markers of cardiovascular disease, interventions
by the pharmacist at this clinic were previously quantified in many additional disease states, such as asthma/COPD, chronic pain, Hepatitis C co-infection, and anticoagulation. 56 Although the benefits of incorporating a clinical pharmacist into the HIV primary care setting are numerous, cost may be viewed as a significantly limiting factor. This study was not originally designed to compare costs between the two study groups.
However, we may informally estimate potential cost savings based on values from the literature and databases of commercially available insurance claims in regards to our study outcomes (Table 4) . [57] [58] [59] [60] [61] All values are converted to 2015 US dollars based on the Consumer Price Index 62 . As these cost estimates are synthesized from different sources, patient cohorts, settings, and study years, interpretations should be made cautiously. It was estimated that $3329 per patient would be saved for the interdisciplinary group in terms of financial returns on smoking cessation and emergency department/hospital utilization due to hypertension, diabetes mellitus, hyperlipidemia, and drug-drug interactions. This value may be over-estimated when compared to our results, as not all of these outcomes achieved statistical significance. To our knowledge, there is no pharmacoeconomic study evaluating the effects of a multidisciplinary team with pharmacist interventions for HIV-infected patients. Future research in this area is warranted to further justify our results.
CONCLUSION
Pharmacist involvement in an HIV primary care clinic appears to result in more appropriate management of chronic co-morbidities in a cost-effective manner, although positive long-term outcomes may be difficult to establish in a complicated, urban population. We believe this data supports the expansion of clinical pharmacist involvement in HIV primary care centers to establish interdisciplinary team models as the standard for best practice. 4 General linear model was performed to adjust for covariate: baseline LDL (p<0.001) 5 Independent t-test was performed 6 General linear model was performed to adjust for covariate: baseline HbA1c (p<0.001) 3 Only for those who had drug-drug interactions at baseline 
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